Major technical advance in astronomy improves diagnosis of eye diseases

January 17, 2003

BLOOMINGTON, Ind. -- A major technical advance in astronomy is making it possible for scientists to see individual living cells of the human retina clearly for the first time. This will greatly improve doctors' ability to diagnose diseases of the retina such as glaucoma at an early stage, when intervention and treatment can prevent blindness.

A technology called adaptive optics allows astronomers to see distant stars with the ground-based Keck Telescope in Hawaii almost as well as with the Hubble Space Telescope. Adaptive optics is a computerized system that continually measures optical flaws and then automatically corrects for them. It eliminates the distorting effects of Earth's turbulent atmosphere when astronomers are viewing objects in space with the Keck Telescope.

Donald T. Miller and Larry Thibos, professors in the Visual Sciences Group at the Indiana University School of Optometry in Bloomington, are applying adaptive optics to the problem of eliminating the distorting effects of a patient's eye so they can examine the living cells of the retina at the back of the person's eye. Their high-quality instruments for examining the retina correspond to the astronomer's telescope; the cells of the retina correspond to stars in space; and the patient's eye corresponds to Earth's atmosphere since it is constantly changing, preventing images of the retina from becoming clearly focused for the examiner.

"The eye is a mediocre optical instrument compared with the tools that ophthalmologists and scientists have available," Thibos explained. "The eye is inferior because it is made out of biological materials, it grows, it is constantly changing and controlling its own growth, it has numerous flaws, and it gets worse as the person gets older."

Thibos has devised an instrument called an ocular aberrometer that measures optical aberrations in the eye by sensing errors in optical wavefronts reflected from the retina. Miller has developed technology that corrects those errors to obtain high-resolution images of the retina. "That's where the state of the art is right now," Thibos said.

Though their combined instrumentation is not yet in clinical practice, "It looks like there will be a large explosion of this in the next few years," Miller said. "Right now there are about five operational sytems in the world in laboratories, including here at IU."

When the equipment becomes available for clinics, a doctor will be able to get a clear view of individual cells in the retina and determine whether the cells are healthy or diseased, instead of having to wait for visible symptoms of retinal disease to appear. By the time symptoms become apparent, retinal cells often are dead and blindness may be unavoidable. If signs of retinal cell disease can be detected early, there is a much better chance of saving the patient's vision.

"In glaucoma, for example, the actual disease is cells in the optic nerve dying, and right now doctors can't see that happening," Thibos said. "They can only see it after the cells are dead. It may take 10 years for changes in vision caused by glaucoma to show up. They could do much better in treating glaucoma if diagnosis were early."

Age-related macular degeneration is another major application for this technology. "Scientists can now see retinal cells degenerating in the laboratory, but not in the patient's eye," Thibos said. "Early diagnosis would allow much superior treatment and prevention of blindness."
For more information, contact Thibos at 812-855-9842 or and Miller at 812-855-7613 or Their research is funded by the National Eye Institute of the National Institutes of Health and by the National Science Foundation Center for Adaptive Optics.

Indiana University

Related Glaucoma Articles from Brightsurf:

Monitoring glaucoma at home
Glaucoma is a chronic condition that affects cells at the back of the eye.

Study finds novel mechanism that may confer protection against glaucoma
A team of researchers from LSU Health New Orleans Neuroscience Center of Excellence and the University of Copenhagen provides the first evidence that patients with ocular hypertension may exhibit superior antioxidant protection that promotes resistance to the elevated intraocular pressure associated with glaucoma.

AI-supported test for very early signs of glaucoma progression
A new test can detect glaucoma progression 18 months earlier than the current gold standard method, according to results from a UCL-sponsored clinical trial.

New method gives glaucoma researchers control over eye pressure
Neuroscientists have developed a new method that permits continuous regulation of eye pressure without damage, becoming the first to definitively prove pressure in the eye is sufficient to cause and explain glaucoma.

Glaucoma care in prison inmates
Data fromĀ 82 prison inmates treated in a glaucoma clinic at an academic hospital were used in this observational study to report on how treatment and follow-up, including medication adherence, were are managed.

New glaucoma test to help prevent blindness
Researchers have identified 107 genes that increase a person's risk of developing the eye disease glaucoma, and now developed a genetic test to detect those at risk of going blind from it.

Air pollution linked to higher glaucoma risk
Living in a more polluted area is associated with a greater likelihood of having glaucoma, a debilitating eye condition that can cause blindness, finds a new UCL-led study in the UK.

Long-term statin use associated with lower glaucoma risk
A new study brings the connection between statin use and risk of glaucoma into sharper focus.

Health burden of glaucoma has risen worldwide
The health burden of glaucoma has continuously increased around the globe in the past 25 years, according to an Acta Opthalmologica study.

UAlberta scientists first to pinpoint a cause of pigmentary glaucoma
An international team of researchers has identified a gene responsible for the onset of pigmentary glaucoma, which may lead to new therapies for the condition.

Read More: Glaucoma News and Glaucoma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to